| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
61.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.05 - $22.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
35,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$599,727 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
3 |
7 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tarriff Scott |
CEO |
• • – |
2018-03-30 |
4 |
OE |
$4.04 |
$456,940 |
D/D |
113,104 |
1,483,050 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2018-03-06 |
4 |
S |
$53.94 |
$126,220 |
D/D |
(2,340) |
11,374 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2018-03-05 |
4 |
OE |
$0.90 |
$2,106 |
D/D |
2,340 |
13,714 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2018-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2018-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,966 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2018-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,700 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2018-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Ratoff Steven B |
Director |
– • – |
2017-12-18 |
4 |
OE |
$0.90 |
$2,106 |
D/D |
2,340 |
15,664 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2017-08-16 |
4 |
B |
$55.45 |
$19,406 |
D/D |
350 |
700 |
2.74 |
- |
|
| Braunstein Douglas L |
Director |
– • – |
2017-08-09 |
4 |
B |
$48.06 |
$1,001,087 |
I/I |
20,400 |
971,000 |
2.1 |
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2017-06-12 |
4 |
B |
$71.49 |
$25,021 |
D/D |
350 |
350 |
2.74 |
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2017-05-19 |
4 |
B |
$79.69 |
$20,321 |
D/D |
255 |
966 |
2.74 |
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2017-05-16 |
4 |
B |
$82.24 |
$16,448 |
D/D |
200 |
711 |
2.74 |
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
298,214 |
149,107 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-05-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,584,087) |
0 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-04-25 |
4 |
S |
$88.34 |
$4,788,482 |
I/I |
(54,180) |
6,777 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-04-25 |
4 |
OE |
$0.90 |
$1,852,677 |
I/I |
54,180 |
60,957 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-04-03 |
4 |
S |
$83.13 |
$5,105,845 |
I/I |
(61,420) |
3,584,087 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-03-31 |
4 |
S |
$83.02 |
$1,966,661 |
I/I |
(23,689) |
3,645,507 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-03-30 |
4 |
S |
$83.00 |
$516,509 |
I/I |
(6,223) |
3,669,196 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-03-29 |
4 |
S |
$83.01 |
$5,051,574 |
I/I |
(60,855) |
23,274 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-03-28 |
4 |
S |
$83.02 |
$513,230 |
I/I |
(6,182) |
3,734,174 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-03-27 |
4 |
S |
$83.00 |
$3,272,773 |
I/I |
(39,431) |
24,874 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2017-03-23 |
4 |
S |
$82.06 |
$576,489 |
D/D |
(7,025) |
0 |
|
- |
|
| Krill Steven L. |
EVP & Chief Scientific Officer |
• – – |
2017-03-23 |
4 |
OE |
$12.63 |
$88,807 |
D/D |
7,025 |
7,025 |
|
- |
|
222 Records found
|
|
Page 5 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.14 (3.04%) 
